TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01743326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio Frequency Denervation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Study: NCT03726788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 100U
Description: one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 200U
Description: one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide Inj Susp 20 MG/ML
Description: one intra-articular injection of 2 ml Triamcinolone Hexacetonide
Study: NCT03874871

Intervention type: PROCEDURE
Intervention: Function preserving gastrectomy
Description: Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.

Intervention type: PROCEDURE
Intervention: Standard gastrectomy
Description: Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
Study: NCT03222765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, metformin, linagliptin, linagliptin + metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, metformin, linagliptin, linagliptin + metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, metformin, linagliptin, linagliptin + metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, metformin, linagliptin, linagliptin + metformin
Study: NCT03079128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Weight Watchers Intervention
Study: NCT00216463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 300 mg subcutaneous injection - every week for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 400 mg subcutaneous injection - every week for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection - every week for 13 weeks
Study: NCT03436225

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone orally.
Description: Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone parenteral.
Description: Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled nebulized Budesonide.
Description: Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled nebulized salbutamol.
Description: Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
Study: NCT00011570

Intervention type: DEVICE
Group type: OTHER
Intervention: Bladder & Bowel Control
Study: NCT03056937

Intervention type: OTHER
Intervention: Bariatric surgery
Description: evaluations pre and post bariatric surgery.

Intervention type: OTHER
Intervention: Bariatric surgery
Description: evaluations pre and post bariatric surgery.

Intervention type: OTHER
Intervention: Control
Description: without intervention, it will be performed only evaluations
Study: NCT00059865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT03453125

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spanish modified Story Memory Technique (mSMT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish modified Story Memory Technique (mSMT)
Study: NCT04423263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral internal iliac artery balloon occlusion
Description: Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
Study: NCT00699491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT03701256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound guided TAP bloc
Description: In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus
Description: In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
Study: NCT03472508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study: NCT00254644

Intervention type: PROCEDURE
Intervention: Morphological and functional MRI
Description: one time

Intervention type: PROCEDURE
Intervention: Morphological and functional MRI
Description: one time
Study: NCT02389491

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal density formula (Necocate)
Description: In control group,there are 32 infants

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high density formula(Infatrini)
Description: In intervention group,there are 32 infants
Study: NCT03571893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Freestyle (Flex)
Description: Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIY Personal Plan
Description: Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
Study: NCT05035355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a weaning protocol
Description: a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
Study: NCT03343730

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-mydriatic color fundus photography with the RetinaVue camera
Description: This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Referral for dilated eye exam with an eye care professional
Description: All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
Study: NCT00533663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: every other week (during their infusion)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided relaxation
Study: NCT04506502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The MMS device will be used to perform the treatments.
Study: NCT03423849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25mg/m2,day 1 and day 8, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25mg/m2,day 1 and day 8, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m2,day 1 and day 8, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2,day 1,every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250mg/m2,day 1 to day 14, every 3 weeks
Study: NCT01736956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Aortic Valvuloplasty
Description: Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
Study: NCT00456313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLIXOTIDE and SERETIDE
Description: comparator
Study: NCT03557567

Intervention type: DIAGNOSTIC_TEST
Intervention: NGS molecular screening

Intervention type: DIAGNOSTIC_TEST
Intervention: NGS molecular screening
Study: NCT04664348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posteroanterior mobilization (neutral)
Description: Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posteroanterior mobilization (extension)
Description: Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.
Study: NCT00566384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
Study: NCT04900532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol rich fraction
Description: Supplementation with a Vitamin E compound.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
Study: NCT02255435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 2.5 mg
Study: NCT00304083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT02255435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 150 mg
Study: NCT02731742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1966
Description: MK-1966 administered as an intravenous (IV) infusion
Study: NCT03278054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Treatment with hand instruments
Description: Root canal treatment was performed with K files.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with Protaper instruments
Description: Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with hybrid instrumentation
Description: Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
Study: NCT03285022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial caries removel techniques
Description: Removel of all superfacial dentin and leaving the inner affectted dentin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial caries removel techniques
Description: Removel of all superfacial dentin and leaving the inner affectted dentin
Study: NCT00941629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
Study: NCT00304083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT02029300

Intervention type: OTHER
Group type: OTHER
Intervention: Fiberoptic Intubation through the nasal route
Study: NCT00304083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery
Study: NCT02029300

Intervention type: OTHER
Group type: OTHER
Intervention: Fiberoptic intubation through the oral route
Study: NCT03629275

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CTX0E03 Drug Product and delivery device
Description: Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
Study: NCT01489813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: 30 mg of genistein supplement by mouth three times daily (PO TID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pills will be taken by mouth three times daily (PO TID).
Study: NCT02754700

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Training
Description: Standardized, comprehensive neuromuscular training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Focused ROBUST Training
Description: Biofeedback training focused on the hip extensors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Focused ROBUST Training
Description: Biofeedback training focused on knee abduction
Study: NCT01170533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole and pantoprazole
Description: The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole and pantoprazole
Description: The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
Study: NCT00304083

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy
Study: NCT02420210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01388465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging
Description: Daily assessment followed by feedback
Study: NCT04167410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glycaemic management protocol implemented to clinic
Description: Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
Study: NCT03356821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: One dose of 50x10\^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
Study: NCT02410928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laringoscopy
Description: the vocal cords will be visualized after extubation with direct laringoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic nasal laringoscopy
Description: the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonograph
Description: the vocal cords will be visualized after extubation with fiberoptic ultrasonography
Study: NCT01194492

Intervention type: RADIATION
Group type: OTHER
Intervention: Albumin transcapillary escape rate (125I-albumin)
Description: Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
Study: NCT01256684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.